Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization, announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 10,851,676 shares of the Company’s common stock pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission.
June 2, 2021
· 5 min read